Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TorreyPines Therapeutics has initiated a second phase I single and multiple dose study in healthy elderly volunteers for NGX267, a novel treatment for Alzheimer's disease.
Subscribe to our email newsletter
The study will enroll approximately 64 healthy men and women between the ages of 65 and 80, reflecting the age of the primary Alzheimer’s disease population. Investigators will evaluate the safety, tolerability and single and multiple dose pharmacokinetics of NGX267, as well as pharmacodynamic measures including effects on CSF levels of AB1-42 and neuropsychological tests.
This study follows successful completion of the company’s first phase I study with this compound. In the first study, NGX267 was administered as single doses to healthy adult males and it was shown to be well tolerated.
In preclinical studies, NGX267, a selective muscarinic agonist, has shown the potential to both reduce symptoms and slow disease progression. Currently approved Alzheimer’s disease therapies only treat symptoms of the disease.
“We believe our M1 agonist has the potential to offer disease modification as well as symptomatic relief without the level of side effects previously found with other M1 agonists,” said Dr Neil Kurtz, president and CEO of TorreyPines. “A therapy that targets both the cause and symptoms of Alzheimer’s disease would be a significant breakthrough in the treatment of this devastating illness.”